Neurizon Therapeutics has dosed over 50% of participants in the HEALEY ALS Platform Trial's Regimen I, exceeding recruitment expectations after expanding the cohort from 160 to 240 patients. The accelerated pace puts the company on track for last patient dosing in Q2 2027 and topline results by early Q3 2027.
- More than 50% of Regimen I participants dosed in HEALEY ALS trial
- Cohort expanded from 160 to 240 due to strong recruitment momentum
- 167 participants assigned and 129 dosed as of 9 June 2026
- 78 clinical sites activated across the United States
- Last patient dosing expected in Q2 2027, topline data in early Q3 2027
Rapid Dosing Surpasses Expectations in Expanded Trial Cohort
Neurizon Therapeutics (ASX:NUZ) has cleared a significant milestone in its HEALEY ALS Platform Trial, dosing over half of the participants in Regimen I ahead of schedule. The trial, which evaluates the lead drug candidate NUZ-001 for Amyotrophic Lateral Sclerosis (ALS), has seen 129 of 240 participants dosed as of 9 June 2026, with 167 assigned to the regimen.
This progress follows the recent expansion of Regimen I from 160 to 240 participants, a move prompted by stronger-than-expected recruitment and the absence of competing regimens during enrolment. The larger cohort is designed to yield a more robust and informative dataset without altering the original statistical assumptions for efficacy analysis.
Operational Efficiency and Broad Engagement Drive Momentum
The trial now operates across 78 activated clinical sites throughout the United States, underscoring the operational strength of the HEALEY ALS Platform Trial network. Neurizon credits the rapid dosing pace to strong investigator engagement, efficient patient progression through recruitment, screening, randomisation, and treatment, as well as active involvement from the ALS community.
Interim Executive Chairman Sergio Duchini highlighted that surpassing the 50% dosing mark shortly after the cohort expansion reflects the platform’s execution capabilities and the enthusiasm surrounding NUZ-001. He emphasised that the accelerated enrolment and dosing exceed original expectations and bolster confidence in the trial’s timeline.
On Track for Critical Milestones in 2027
Neurizon anticipates completing last participant dosing in Regimen I by the second quarter of calendar year 2027, with topline results expected in early Q3 2027, subject to continued recruitment and operational factors. These milestones are pivotal for advancing NUZ-001’s clinical development and potential regulatory and commercial opportunities.
The HEALEY ALS Platform Trial itself is a multi-centre, double-blind, placebo-controlled adaptive Phase 2/3 study conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in partnership with the Network of Excellence for ALS (NEALS). It aims to accelerate the development of new ALS therapies through a competitive drug selection process.
Bottom Line?
Neurizon’s accelerated dosing and expanded cohort position it well for robust data delivery next year, but timelines remain contingent on sustained recruitment and operational execution.
Questions in the middle?
- Will recruitment momentum sustain through to full enrolment and last patient dosing?
- How might the expanded dataset influence NUZ-001’s regulatory and commercial prospects?
- What operational challenges could affect the timing of topline results in early Q3 2027?